RxDoctor Payments Data

Joshua Gratwohl, PA

Physician Assistant · Salem, ORNPI 1386370898

Payments from drug & device makers

$3,854in general payments, 2019–2025

Across 199 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$775
  • Novo Nordisk$641
  • Xeris Pharmaceuticals, Inc.$616
  • Amgen$375
  • Bayer$301
  • Boehringer Ingelheim$296
  • plus $850 from 13 others

What the payments were for

  • Food & beverage$3,76898%
  • Education$862%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,854 in reported general payments places this provider in the 95th percentile of 1,756 physician assistant providers in Oregon.

See all physician assistant providers in Oregon

Medicare billing

Part B allowed, 2024
$26,479
Medicare patients
135
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide292$413,451
JardianceEmpagliflozin177$218,481
TymlosAbaloparatide50$130,943
MycapssaOctreotide Acetate12$117,603
TrulicityDulaglutide77$113,806
MounjaroTirzepatide55$96,891
GenotropinSomatropin20$55,008
Tresiba Flextouch U-100Insulin Degludec38$37,882
FarxigaDapagliflozin Propanediol31$31,263
Tresiba Flextouch U-200Insulin Degludec12$26,375
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$22,825
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$17,935
Lantus SolostarInsulin Glargine,hum.Rec.Anlog110$14,858
Gvoke Hypopen 2-PackGlucagon23$14,826
Humalog Kwikpen U-100Insulin Lispro52$14,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$641$431,512317 claims
Boehringer IngelheimJardiance$296$218,481177 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$775$213,551159 claims
PfizerGenotropin$16$55,00820 claims
AstraZenecaFarxiga$114$31,26331 claims
Sanofi-aventis U.S. LLCAdmelog, Lantus$59$4,93030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,756 physician assistant providers in Oregon.

Other physician assistant in Salem

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →